

Results: All 23 pts enrolled by 15-Apr-08 received ≥ 1 dose of MLN8237, with a median of 2 cycles (range, 1–11+), and 9 (39%) pts were still on study. No DLTs were observed for 5–80 mg. At 80 mg 2 pts experienced G1–2 neutropenia on days 8 or 15. At 150 mg, 3 of 6 pts had DLTs: (a) prolonged G3–4 neutropenia requiring delay of cycle 2 at a reduced dose of 80 mg; (b) G3 mucositis/oral candidiasis requiring hospitalization and dose reduction to 80 mg for cycle 2; (c) G3 somnolence with concurrent initiation of a long-acting opiate and confusion/agitation on day 2 (MLN8237 was discontinued). Alopecia was seen in 1 pt at 80 mg and 2 pts at 150 mg. MLN8237 was rapidly absorbed (mean T_{max} , 1–4 h). Mean AUC_{0-24h} and C_{max} increased with dose. At 150 mg, mean steady-state C_{max} was 4.6 μM and mean steady-state C_{24h} was $\geq 1 \mu M$, the estimated efficacious exposure in preclinical models. Day 7 concentrations were $\geq 1 \mu M$ for ≥ 12 h in 1 of 3 pts at 80 mg (C_{max} , $\sim 4 \mu M$) and 4 of 6 pts at 150 mg (C_{max} , $\sim 5 \mu M$). Mean $t_{1/2}$ was 30–40 h for 5 to 80 mg, and 15 h at 150 mg. One pt had preliminary evidence of antitumor activity after 2 cycles (cycle 1, 150 mg; cycle 2, 80 mg) in platinum-refractory, radiation-resistant, metastatic ovarian cancer. 4 pts received 6–13+ cycles. Effects of MLN8237 in serial skin biopsies will be presented to support proof-of-mechanism.

Conclusions: Dosing with MLN8237 for 7 days in 21-day cycles was well-tolerated. Anti-proliferative clinical effects of MLN8237 were first noted at 80 mg and DLTs were seen at 150 mg. Clinically significant benzodiazepine-like side effects were not observed, except when MLN8237 was administered with long-acting opiates. Planned dose groups include 110 mg QD and 70–100 mg twice daily. Lower doses over 14–21 days will be evaluated.

281

POSTER

Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

E. Dees¹, J.R. Infante², R.B. Cohen³, B. O'Neil¹, H. Burris², M. von Mehren³, G. Gray⁴, K. Galvin⁵, M. Manfredi⁶, O. Eton⁶. ¹UNC Lineberger Comprehensive Cancer Center, Hematology/Oncology, Chapel Hill, NC, USA; ²Sarah Cannon Research Institute, Drug Development, Nashville, USA; ³Fox Chase Cancer Center, Medical Oncology, Philadelphia, USA; ⁴Millennium Pharmaceuticals Inc., Drug Development, Cambridge, USA; ⁵Millennium Pharmaceuticals Inc., Cancer Pharmacology, Cambridge, USA; ⁶Millennium Pharmaceuticals Inc., Oncology Clinical Research, Cambridge, USA

Background: MLN8054 is a selective small-molecule inhibitor of Aurora A kinase. This phase I clinical trial examined the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8054.

Materials and Methods: MLN8054 was given orally for 7–21 consecutive days followed by 14 days break (21–35 day cycles). Cohorts of 3–6 patients (pts) with advanced solid tumors at 3 centers in the US were enrolled in escalating cohorts until dose-limiting toxicity (DLT) was seen in ≥ 2 of 6 pts. Serial blood samples were collected to estimate PK. The PD effects of MLN8054 on Aurora A kinase were inferred from accumulation of mitotic cells in basal epithelium in 2–3 mm skin biopsies obtained before and after dosing.

Results: 61 pts were treated (38 men, 23 women, median age 60). Tumor types included gastrointestinal (30), lung (9), genitourinary (8), sarcoma (8), breast (3), and other (3). Dose levels evaluated were 5, 10, 20, 30 and 40 mg/day in single daily doses (QD) for 7 days; 25, 35, 45 and 55 mg/day in four divided doses (QID) for 7 days; and 55, 60, 70 and 80 mg/day in QID doses for 7–21 days plus methylphenidate (MP) 5–10 mg with daytime doses to reduce somnolence. Pts received a median of 2 cycles (range, 1–14). Maximum tolerated doses were 30 mg/day for QD dosing, 45 mg/day for QID dosing, and 60 mg/day for QID dosing plus MP. Reversible Grade 3 benzodiazepine-like effects, especially somnolence, were the DLTs in all dosing permutations, usually starting in the first week of dosing. No dose studied was associated with significant myelosuppression or mucositis. MLN8054 was rapidly absorbed and exposure was dose-proportional. Terminal half-life was 30–40 hours. Skin biopsies were evaluable both pre- and post-treatment in 52 pts. Accumulation of mitotic cells was observed within 24 hours after either the first or last daily dose; the level of this effect varied by pt. While no RECIST responses were seen, 3 pts had stable disease for more than 6 cycles.

Conclusions: MLN8054 dosing for up to 21 days of a 35-day cycle was feasible. Despite divided daily dosing and MP, reversible benzodiazepine-like effects, especially somnolence, continued to be dose-limiting. PD studies suggested that Aurora A was inhibited in the skin of some pts. Studies of MLN8237, a second-generation Aurora A kinase inhibitor, are ongoing.

282

POSTER

Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

P. Schöffski¹, H. Dumez¹, S.F. Jones², C. Fowst³, P. Gerletti³, H. Xu⁴, J. Jakubczak⁴, J. Infante², N. Mellaerts¹, H.A. Burris². ¹University Hospitals Leuven, Leuven Cancer Institute Department of General Medical Oncology, Leuven, Belgium; ²Sarah Cannon Research Institute, Drug Development Unit, Nashville, TN, USA; ³Pfizer Italia, Global Development, Milan, Italy; ⁴Pfizer Inc, Global Development, New London, CT, USA

Background: Aurora kinases are a family of kinases that are key regulators of mitosis and cytokinesis, and have been associated with carcinogenesis. Aurora kinase A is commonly amplified in solid tumors and has been established as an oncogene. Aurora B over-expression in tumors leads to defects in mitosis and is associated with increased invasiveness. PF-03814735 is a novel oral ATP-competitive, reversible inhibitor of Aurora A and B kinases with a broad spectrum of preclinical antitumor activity.

Material and Methods: This is an ongoing dose-escalation study to identify the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose, to assess the pharmacokinetics (PK), and to obtain proof-of-mechanism (by assessment of pH3 inhibition in tumor biopsies and FDG-PET) with PF-03814735 administered daily for 5 or 10 consecutive days q3w.

Results: In the 5-day schedule, 25 patients received a median of 2 cycles (1–8) across 7 dose levels from 5–100 mg/day. The most common primary diagnoses in this cohort were non-small cell lung cancer, colorectal cancer and malignant melanoma. Dose-limiting febrile neutropenia was observed in 2/7 patients treated at 100 mg/day. The most commonly observed treatment-related adverse events were mild to moderate diarrhea (44%), vomiting, anorexia, fatigue, (25% each) and nausea (20%). MTD expansion for safety and pharmacodynamics is currently ongoing. No objective response has been observed so far. Serum exposure of PF-03814735 (C_{max} and AUC) increased in a dose-proportional manner at all dose levels tested, indicating a linear PK at least up to 100 mg/day. After a single dose, the total clearance of PF-03814735 is 1.25 ± 0.39 L/h and the median $t_{1/2}$ was 20.2 h. Dose escalation on the 10-day treatment schedule is ongoing. Three patients have been treated at 40 mg/day, and 2 patients have been treated at the next dose level (50 mg/day).

Conclusions: For the 5-day treatment schedule, the MTD was defined as 80 mg/day. The effects of PF-03814735 on tumor metabolism and pH3 levels are currently being evaluated. The 10 day schedule is open for accrual, and results will be reported.

283

POSTER

Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients

F. Robert¹, H. Hurwitz², H. Uronis², C. Verschraegen³, R. Advani⁴, A. Chen⁴, G.L. Messerschmidt⁵, N. Havrilla⁶, P. Taverna⁷, M. Evanchik⁸. ¹University of Alabama, Hematology & Oncology, Birmingham, AL, USA; ²Duke University, Medical Oncology, Durham, NC, USA; ³University of New Mexico, Hematology Oncology, Albuquerque, NM, USA; ⁴Stanford University, Oncology, Palo Alto, CA, USA; ⁵Sunesis Pharmaceuticals, Medical Science, South San Francisco, CA, USA; ⁶Sunesis Pharmaceuticals, Clinical Operations, South San Francisco, CA, USA; ⁷Sunesis Pharmaceuticals, Pharmacology, South San Francisco, CA, USA; ⁸Sunesis Pharmaceuticals, Pkdm, South San Francisco, CA, USA

Background: The Aurora Kinases are a family of serine/threonine kinases (Aurora kinases (AK) A, B, and C) that play a key role in orderly progression through mitosis and have been implicated in a wide range of human tumors. Elevated expression levels of AKs have been detected in a high percentage of melanoma, colon, breast, ovarian, gastric, and pancreatic tumors, and in a subset of these tumors the AURKA locus (20q13) is amplified. SNS-314, a novel aminothiazole-derived urea, is a selective inhibitor of AKs A, B, and C with IC50 values in the low nanomolar range.

Methods: The trial is a standard 3+3 phase 1 dose escalation study design. Patients (pts) with advanced solid tumors were treated with SNS-314 given as a three hour IV infusion once weekly X 3 (28 day cycle). Primary endpoints of the study are: safety, tolerability, and DLT assessment. Secondary endpoints of the study include: pharmacokinetic (PK) evaluation on Days 1 and 15 and pharmacodynamic (PD) evaluation. PD evaluation assesses histone H3 phosphorylation (pHH3) in cells obtained by punch skin biopsies.

Results: A total of 19 pts (10M/9F) have been enrolled into 5 cohorts: median age = 59 (range 38–66). The initial dose was 30 mg/m² with subsequent dose escalation doubling until first observation of clinically significant \geq Grade 2 related toxicity then according to a modified Fibonacci schema. No dose limiting hematological or non-hematological toxicities